Publications
Detailed Information
Comparative analysis of overall survival of patient with non-small cell lung cancer harboring anaplastic lymphoma kinase fusion : 역형성 림프종 인산화효소 융합-양성 비소세포폐암 환자의 전체생존기간에 대한 비교연구
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Advisor
- 허대석
- Major
- 의과대학 의학과
- Issue Date
- 2013-02
- Publisher
- 서울대학교 대학원
- Keywords
- Anaplastic lymphoma kinase ; epidermal growth factor receptor ; non-small cell lung carcinoma ; overall survival ; tyrosine kinase inhibitor
- Description
- 학위논문 (석사)-- 서울대학교 대학원 : 의학과 분자종양의학 전공, 2013. 2. 허대석.
- Abstract
- Background and purpose:
The aim of this study was to examine the overall survival (OS) of patient with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusion, who were treated in the pre-ALK inhibitor era and to compare the survival with a matched case cohort of ALK-wildtype (WT) patients.
Methods:
Data from 1,166 stage IIIB/IV patients with non-squamous histology were collected from the NSCLC database of Seoul National University Hospital between 2003 and 2009. ALK FISH was performed on 262 cases that were either EGFR wild-type (WT) or non-responders to prior EGFR tyrosine kinase inhibitor (TKI) therapy. Survival analysis was conducted to compare the OS between 3 groups: 1) ALK fusion-positive, 2) EGFR mutation-positive and 3) ALK-WT/EGFR-WT (WT/WT). Progression-free survival (PFS) of 1st-line platinum-based doublet chemotherapy and EGFR TKIs was also analyzed.
Results:
Twenty-three cases were ALK fusion-positive by FISH and did not receive ALK inhibitors during the follow-up period. The median OS of ALK fusion-positive, EGFR mutation-positive and WT/WT patients was 12.2, 29.6, and 19.3 months, respectively (P-value
vs. EGFR mutation-positive: 0.001, vs. WT/WT: 0.127). The PFS of 1st-line platinum-based chemotherapy for the 3 groups was not different. However, the PFS of EGFR TKIs was shorter in ALK fusion-positive patients, compared with the other two groups (P-value
vs. EGFR mutation-positive: < 0.001, vs. WT/WT: 0.021).
Conclusion:
Before the introduction of ALK inhibitors, ALK fusion-positive patients experienced the shortest survival, albeit not statistically different from WT/WT patients. Although their responses to platinum-based chemotherapy were not different from comparator groups, ALK fusion-positive patients were even more resistant to EGFR TKI treatment than were WT/WT patients.
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.